Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EIK1006
- Development stage
- Preclinical
- Lead developer
- Eikon Therapeutics
- Modality
- Small Molecules
01
Overview
EIK1006 is a next-generation small molecule androgen receptor (AR) antagonist being developed by Eikon Therapeutics. It is designed to target and inhibit the androgen receptor, including multiple clinically emergent variants that often lead to resistance in standard-of-care therapies. Currently in IND-enabling studies, EIK1006 is primarily being investigated for the treatment of prostate cancer and other androgen receptor-driven malignancies. The drug was developed using Eikon's proprietary platform, which utilizes high-resolution live-cell imaging to track protein dynamics and identify novel therapeutic candidates.
02
Targets
AR (Adrenergic receptors)
Beyond the preview
Go deeper on EIK1006.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EIK1006.